The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2026 | Real-world data support olutasidenib after venetoclax in IDH1-mutated AML
Pinkal Desai, MD, MPH, Weill Cornell Medicine, New York, NY, reviews real-world outcomes with olutasidenib in patients with relapsed/refractory IDH1-mutated AML previously treated with venetoclax, highlighting encouraging response rates, durable remissions, and the potential role of this targeted therapy in current treatment sequencing. This interview took place at the 31st Congress of the European Hematology Association (EHA) in Stockholm, Sweden.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
